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i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8 223patientswhowere on dialysis. This study comparedCinacalcet
with placebo in 3883 patients undergoing dialysis. Limited
number of interventions are found to improve cardiovascular
health in CKD undergoing dialysis. Secondary hyper-
parathyroidism has emerged as one of the most important
risk factors for cardiovascular disease and thus, high rate of
death and cardiovascular events in end stage renal disease.3
Although this trial result is non-definitive but after adjust-
ment to the baseline characteristics there was nominally sig-
nificant 12% reduction in cardiovascular risk, 15% reduction in
primary composite end point and 17% reduction in mortality.
One has to understand the context of the patients who are
on dialysis, frequently have poor health and high mortality
(20% inUnited States) andmorbidity (median 2 hospitalization
and 12 hospital days per year). Patients have multi organ
involvement with average pill burden of 19. Cinacalcet
reduces parathyroidectomy by 50%. The study includes
Cohorts from various geographic area, race, ethnicity, age and
underlying kidney and cardiovascular diseases.
Analysis adjusted for baseline characteristics on taking
into account the effect of parathyroidectomy and kidney
transplantation a nominally significant reduction on death on
first Myocardial Infarction, hospitalization for unstable
angina, heart failure and peripheral vascular disease (risk
reduction 10e15% and absolute reduction of 2e3%).r e f e r e n c e s
1. Kidney disease improving global outcomes (KDIGO) CKD-MBD
Work Group. Kidney Int Suppl. 2009;76:S1eS130.
2. Cunningham J, et al. Kidney Int. 2005;68:1793.
3. Chertow GM, et al. Am Soc Nephrol. 2007;2:898e905.
Ajay Kumar Sinha
Associate Editor, IHJ, India
E-mail address: sinha_ajaykr@yahoo.co.inGregg W. Stone, Alexandre Abizaid, Sigmund Silber, et al.,Prospective, randomized, multicenter evaluation of a poly-
ethylene terephthalate micronet mesh-covered stent
(MGuard) in ST-segment elevation myocardial infarction: the
MASTER trial. J Am Coll Cardiol 60 (2012) 1975e1984
1. Introduction
The enemy of revascularization using primary PCI during
STEMI intervention is risk of distal embolizationwith capillary
plugging which leads to reduced tissue reperfusion. Several
pharmacological agents, as well as mechanical devices (i.e.
manual aspiration catheters/mechanical thrombectomy,
proximal and distal protection devices) were introduced, in
the last years, to reduce the risk of angiographic complica-
tions during percutaneous coronary intervention and to
improve myocardial reperfusion.1,2 Despite the use of these
agents still distal embolization is common which leads to no-
reflow phenomenon.1,2
Recently, the MGuard stent (InspireMD, Tel Aviv, Israel), a
bare metal stent covered by micron level mesh, which allowsto prevent distal embolization by blocking the athero-thrombi
prolapse through the stent struts during deployment.3
Dr. Gregg W. Stone presented the late-breaking findings
from the MASTER study were presented in a late-breaking
session at TCT 2012 that revealed a new stent in STEMI
patients undergoing emergent PCI to increase the rate of com-
plete ST-segment resolution comparedwith conventional BMS
and DES.
2. Objectives
MASTER study sought to evaluate the potential utility of a
novel polyethylene terephthalate micronet mesh-covered
stent (MGuard) in patients with acute ST-segment elevation
myocardial infarction (STEMI) undergoing percutaneous cor-
onary intervention (PCI).
3. Study design
 The MASTER trial is a prospective, multicenter, randomized
study designed to compare the incidence of complete
(70%) ST-segment resolution with PCI using bare metal or
drug-eluting stents (the control arm) versus PCI with the
MGuard stent,measured 60e90min after the last angiogram
(primary endpoint).
 Secondary endpoints include the rates of TIMI flow and
myocardial blush, and clinical outcomes through 1-year
follow-up.
 The study has enrolled 432 patients with STEMI undergoing
primary or rescue angioplasty within 12 h of symptom
onset, and includes sub studies with cardiac magnetic res-
onance imaging and quantitative coronary angiography to
evaluate infarct size, micro vascular obstruction and
angiographic restenosis.
 Study population for trial enrolled a total 433 STEMI patients
who presentedwithin 12 h of symptomonset, at 50 sites in 9
countries.
 These enrolees were randomly assigned to receive com-
mercially available stents (n ¼ 216; 60% BMS; 40% DES) or
MGuard (n ¼ 217). The two groups had equal baseline
characteristics.3
4. Results
 Significantly more patients treated with the MGuard
EPS achieved the primary endpoint of post-procedure
of complete ST resolution (a measure of blood flow
restoration to the heart muscle) compared to control arm
(57.8% vs. 44.7%, p ¼ 0.008), a relative improvement of 29%
[Fig. 2].
 When compared to control, the MGuard EPS showed a sig-
nificant improvement in coronary artery blood flow,
including (1): superior rates of restoring normal blood flow
(TIMI 3 flow) (91.7% vs. 82.9%, p ¼ 0.006, a relative
improvement of 10.6%); and (2) significantly less incomplete
blood flow (TIMI 0/1 flow) post PCI (1.8% vs. 5.6%, p ¼ 0.01, a
relative improvement of 67.9%).
 The trial showed a trend toward lower mortality (0% vs.
1.9%, p ¼ 0.06) at 30 days and smaller infarct size as
Fig. 1 e AeD The MGuard stent has a 316L stainless steel frame with 100-mm strut thickness. It is manufactured in
diameters ranging from 2.0 to 4.0 mm and in lengths ranging from 11 to 39 mm. The crossing profile ranges from 1.0 to
1.3 mm. The MGuard prime stent is the MGuard prime stent is similar in configuration, but has an L605 cobalt chromium
alloy frame with 80-mm strut thickness and slightly lower crossing profile. It is manufactured in diameters ranging from 2.5
to 4.0 mm and in lengths ranging from 13 to 38mm. The polyethylene terephthalate micronet is identical on both stents and
has a fiber width of 20 mm and an expanded aperture size of 150 3 180 mm.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8224measured by post-procedure cardiac MRI (17.1 g vs. 22.3 g,
p ¼ 0.27) in the MGuard EPS arm versus control.
 There was no difference between the groups in the secon-
dary endpoint of myocardial blush grade (MBG), which is an
angiographic measure of blood flow to the cardiac muscle
(MBG2/3 83.9% vs. 84.7%, p ¼ 0.81).3
5. Conclusions
Among patients with acute STEMI undergoing emergent
PCI, the MGuard micronet mesh-covered stent com e paredFig. 2 e The primary endpoint of complete ST resolution
was achieved in 29% more compared to routine PCI using
BMS/DES [control arm] while partial and absent ST
resolution comparable to control arm.with conventional metal stents resulted in superior rates
of epicardial coronary flow and complete ST-segment
resolution.
6. Clinical perspective
Suboptimal myocardial reperfusion after PCI in STEMI is
common and results in increased infarct size and mortality
(5-year mortality 18.2% with no-reflow vs. patients with good
reflow9.5%). The no-reflow is strong predictor of 5-year mor-
tality[Fig. 3].2Fig. 3 e No-reflow defined as TIMI 0/1/2, or TIMI 3
with MBG 0/1. G. Ndrepepa et al compared 5-year
outcome of 410 patients with no-reflow vs. 996
patients with reflow. (Kaplan-Meier estimates of 5-year
mortality 18.2% and 9.5%, respectively; odds ratio: 2.02;
95% confidence interval: 1.44 to 2.82; p< 0.001).
Fig. 4 e A showing comparison of blush grade and their
predictor for adverse events for bare metal stent [BMS],
thrombo-aspiration [TA] and MGuard. B showing
comparison of ST resolution and their predictor for adverse
events for bare metal stent [BMS], thrombo-aspiration [TA]
and MGuard. Data on this slide for bare metal stent [BMS],
thrombus aspiration [TA] and MGuard are derived from
different sources. Please note a head to head study has not
been conducted. BMS (n[ 665, TAPAS & EXPORT Trials) TA
(n [ 655, TAPAS & EXPORT trial aspiration arm) MGuard
(n [ 234, MAGICAL, Piscione, iMOS, Lindefjeld, Gaul).
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 8 225Covered stents have been tried for embolic protection
before but they used a tightly woven material that ended up
squeezing friable material out like toothpaste rather than
trapping it.4 The high density of the covered stent is detri-
mental to healing and endothelization process, and also
blocks all side branches large and small.
7. MGuard stent: the technology
InspireMD has developed its proprietary stent system tech-
nology, MGuard which is CE-Mark approved.
The MGuard is a novel thin-strut metal stent [a balloon-
expandable metallic scaffold] with mesh sleeve fibers of
polyethylene terephthalate micronet attached to its outer
surface designed to trap and exclude thrombus and friable
atheromatous debris to prevent distal embolization
[Fig. 1AeD].
The net is made of a single knitted PET fiber, and it is
attached only to the proximal and distal edges of the stent.
The net expands seamlessly during stent deployment.
MGuard’s net is completely bio-stable.5
MGuard is deployed exactly like a typical balloon inflated
stent after pre-dilatation if necessary and post dilatation is
recommended whenever there is situation of incomplete
apposition after stent deployment.
The net reduces the risk of plaque rupture and emboliza-
tion providing double protection during and post-procedure.
MGuard addresses risks associated with distal embolization
and no-reflow which simplifies primary PCI and SVG inter-
ventions as it is designed for thrombus containing lesions.
Currently, MGuard is not recommended to be used in bifur-
cation lesions.4
8. MGuard stent: evidence
After successful use of MGuard in First in Man trial in 2008,
11 Single-Arm Trials are done with 630 patients with 458
STEMI patients. They evaluated blush grade, ST-segment
resolution and MACE from 30 days to 1 year. Some of the
important trials are summarized in Table 1. The Landmark
trials were the INSPIRE trial 6 which addressed SVG and ACSTable 1 e Summery of trials of MGuard stent.
Author/PI Patients Year of publication
MASTER trial Gregg Stone et al3 433 2012
INSPIRE trial A. Abizaid et al6 30 2010
MAGICAL trial D. Dudek et al7 60 2010
Interim analysis of a real world
registry (iMOS registry)
A. Danzi et al8
211 2010
Federico Piscione et al9 100 2009patients using MGUARD stent and MAGICAL trial 7 had
STEMI patients but their sample volume was small. Piscione
et al9 showed complete ST resolution with 100% device
success rate.
The iMOS registry is single arm prospective ‘real world’
registry which is ongoing registry with target population ofHighlights
RCT, STEMI patients, randomized 1:1 MGuard vs. BMS/DES.
Superior rates of complete ST resolution (57.8% vs. 44.7%,
p ¼ 0.008). Superior rates of TIMI 3 (91.7% vs. 82.9%, p ¼ 0.006),
0% mortality at 30 days
SVG and native coronaries including ACS, no EPD used, 3.3%
MACE at 30 days, 17% TVR at 1 year 0% death at 1 year
STEMI patients, multicenter, 90% TIMI flow 3, 73% blush grade
3, 0% MACCE at 30 days, 1.7% MACCE at 6 months*
77% STEMI, 87% visible thrombus, 96% TIMI 3 flow, 98%
procedural success, 3.8% MACE at 30 days
STEMI patients (n ¼ 84, excluding cardiogenic shock) 100%
device success, final cTFC ¼ 17.2, 90% MBG 3 90% complete
ST-segment resolution
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 2 1 9e2 2 82261000 patients. Primary endpoint at 6 months of MACE of
Ischemia related death, myocardial infarction (Q wave and
non-Q wave), target lesion revascularization (PTCA or CABG).
They enrolled 81% of AMI patients with 77% of STEMI.
Thrombus was visible in 87% of the cases and 65% of the
patients showed initial TIMI flow of 0/1. Device success was
98% and 96% of the patients gained TIMI 3 flow post-
procedure. STEMI subgroup clinical analysis revealed a 30
days accumulative MACE of 2.5% with 0% TLR.8
As shown in Fig. 4 which compares outcomes of MGuard
stent versus bare metal stent and thrombus aspiration trials
which clearly shows benefit of use of MGuard stent in terms of
blush grade and ST-segment resolution. Though this com-
parison is not head to head comparison but trials using bare
metal stent and thrombus aspiration were compared with
similar parameters of myocardial blush grade and ST-seg-
ment resolution. This comparison showed 84.6% MBG grade 3
with MGuard as compared to only 44% with use of thrombus
aspiration catheter and >70% ST resolution was seen in 79.6%
compared to 56.6% in patients of trials of thrombus aspiration.
But these data need careful assessment with statistical anal-
ysis and there is further need of RCTs comparing them.10
Based on these earlier trials Gregg Stone et al conducted
MASTER trial to prove use of novel stenteMGuard and rec-
ommended in any PCI when a stent implantation is needed
and there is a risk of complication due to distal embolization
of plaque or thrombus.3
Results of the study showed >70% resolution of ST-
segment in MGuard 29% relative to control arm of routine PCI
using either BMS or DES in patients undergoing primary PCI
with thrombus containing lesions but partial or absent reso-
lution of ST-segment was comparable to control arm.
But this study was limited by the fact that the operators
and research coordinators were not blinded to stent assign-
ment, which possibly introduced some bias. The MGuard
stent e which has a higher profile and is less flexible than
standard stents e was unable to reach or cross the lesion in
4.1% of patients while there were no device failures in the
control group.
There were no significant differences at 30 days in rates of
mortality (0% versus 1.9%, p ¼ 0.06), major adverse cardiac
events (1.8% versus 2.3%, p ¼ 0.75), or any other clinical out-
come. The authors noted, however, that the study was
underpowered to evaluate differences in clinical events or
infarct size and/or improved clinical outcomes and concluded
that there is need for further experience with this device with
larger trial.r e f e r e n c e s
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1. Background
The effect of intensified platelet inhibition for patients with
unstable angina or myocardial infarction without ST-segment
elevation who do not undergo revascularization has not been
delineated.
2. Methods
In this double-blind, randomized trial, in a primary analysis
involving 7243 patients under the age of 75 years receiving
aspirin, we evaluated upto 30 months of treatment with pra-
sugrel (10 mg daily) versus clopidogrel (75 mg daily). In a sec-
ondaryanalysis involving2083patients 75yearsof ageor older,
we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel.
3. Results
At a median follow-up of 17 months, the primary end point of
death from cardiovascular causes, myocardial infarction, or
stroke among patients under the age of 75 years occurred in
13.9% of the prasugrel group and 16.0% of the clopidogrel
group (hazard ratio in the prasugrel group, 0.91; 95% con-
fidence interval [CI], 0.79 to 1.05; p¼ 0.21). Similar results were
observed in the overall population. The prespecified analysis
